Pingda Ren Net Worth

What's Pingda Ren's mailing address?

Pingda's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO, CA, 92121.

Insiders trading at Kura Oncology Inc

Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson és Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.

What does Kura Oncology Inc do?

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.

Kura Oncology Inc executives and stock owners

Kura Oncology Inc executives and other stock owners filed with the SEC include:

• Kathleen Ford,
  Chief Operating Officer
• Troy Wilson,
  Chairman of the Board, President, Chief Executive Officer
• Marc Grasso,
  Chief Financial Officer and Chief Business Officer
• James Basta,
  Chief Legal Officer and Secretary
• Dr. Troy Edward Wilson,
  Chairman, CEO & Pres
• Dr. Troy Edward Wilson J.D., Ph.D.,
  Chairman, CEO, Pres & Principal Financial Officer
• Dr. Marc Grasso,
  CFO & Chief Bus. Officer
• Kathleen Ford,
  Chief Operating Officer
• Kirsten Flowers,
  Chief Commercial Officer
• Dr. Marc Grasso M.D.,
  Advisor
• Dr. Stephen Dale M.D.,
  Chief Medical Officer
• Diane Parks,
  Independent Director
• Robert Hoffman,
  Independent Director
• Faheem Hasnain,
  Lead Independent Director
• Thomas Malley,
  Independent Director
• Steven Stein,
  Independent Director
• Mary Szela,
  Independent Director
• Bridget Martell,
  Acting Chief Medical Officer
• Kirsten Flowers,
  Chief Commercial Officer
• Stephen Dale,
  Chief Medical Officer
• Thomas Doyle,
  Principal Accounting Officer & Sr. VP of Fin. and Accounting
• Dr. Nic G. Scalfarotto,
  Sr. VP of Regulatory Affairs
• Dr. Roger Bakale Ph.D.,
  VP and Head of CMC, Clinical & Commercial Manufacturing
• Teresa Brophy Bair Esq., J.D.,
  Chief Legal Officer & Corp. Sec.
• James E. Basta J.D., Esq.,
  Chief Compliance Officer & Corp. Sec.
• Pete De Spain,
  VP of Investor Relations & Corp. Communications
• Teresa Brophy Bair,
  Chief Legal Officer
• Antonio Gualberto,
  Head of Development & CMO
• Pingda Ren,
  SVP Chemistry&Pharma Sciences
• Annette North,
  SVP, General Counsel
• Carol Schafer,
  
• Helen Louise Collins,
  
• Brian T. Powl,
  Chief Commercial Officer
• Thomas James Doyle,
  SVP, Finance & Accounting